On February 4, 2026, Regentis Biomaterials Ltd. appointed Ori Gon as Chief Financial Officer and Chief Business Officer. This event is significant as the company progresses towards the commercial launch of GelrinC in Europe and advances in its Phase III FDA trial in the U.S.